Sarcomas constitute a diverse family of malignancies that can occur anywhere in the body and pose a lethal challenge for the vast majority of afflicted patients. Because of their rarity and heterogeneity, these diseases have a limited medical understanding. These particularly rare malignancies, such as bone and soft tissues sarcomas, have faced a lack of any essentially new and effective therapeutics since the early 1970s, are characterized by poor survivorship, and face modest chemotherapy responses as well as a high rate of recurrence and dissemination.
While for many if not all the sarcomas there is a description of the genetic abnormalities characterizing the disease, (i.e. translocation, amplification and mutation), how mechanistically these abnormalities have an impact on such diseases is still not clear. A better understanding of the underlying oncogenic processes and their regulatory mechanisms is essential to improve the patient outcomes of these devastating diseases.
Furthermore, molecular classification has been proposed for several sarcomas and their impact on prognosis and treatment should be addressed with further research.
This Special Issue of Frontiers in Oncology will present and discuss original articles and review manuscripts aimed at investigating the underlying molecular drivers of bone and soft tissues sarcoma. We invite the submission of manuscripts concerning, but not limited to, the following topics;
- Basic and translational research on biology of sarcomas
- Microarray analysis of human sarcomas
- Identification of new targeted agents for cancer therapy, in the treatment of sarcoma
- Role of the microenvironment in sarcoma progression
- Molecular mechanism underling recurrences
- Genetic aberration in sarcomas
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Sarcomas constitute a diverse family of malignancies that can occur anywhere in the body and pose a lethal challenge for the vast majority of afflicted patients. Because of their rarity and heterogeneity, these diseases have a limited medical understanding. These particularly rare malignancies, such as bone and soft tissues sarcomas, have faced a lack of any essentially new and effective therapeutics since the early 1970s, are characterized by poor survivorship, and face modest chemotherapy responses as well as a high rate of recurrence and dissemination.
While for many if not all the sarcomas there is a description of the genetic abnormalities characterizing the disease, (i.e. translocation, amplification and mutation), how mechanistically these abnormalities have an impact on such diseases is still not clear. A better understanding of the underlying oncogenic processes and their regulatory mechanisms is essential to improve the patient outcomes of these devastating diseases.
Furthermore, molecular classification has been proposed for several sarcomas and their impact on prognosis and treatment should be addressed with further research.
This Special Issue of Frontiers in Oncology will present and discuss original articles and review manuscripts aimed at investigating the underlying molecular drivers of bone and soft tissues sarcoma. We invite the submission of manuscripts concerning, but not limited to, the following topics;
- Basic and translational research on biology of sarcomas
- Microarray analysis of human sarcomas
- Identification of new targeted agents for cancer therapy, in the treatment of sarcoma
- Role of the microenvironment in sarcoma progression
- Molecular mechanism underling recurrences
- Genetic aberration in sarcomas
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
